Cingulate Inc. Adjourns Special Meeting
Ticker: CINGW · Form: DEFA14A · Filed: Aug 23, 2024 · CIK: 1862150
| Field | Detail |
|---|---|
| Company | Cingulate Inc. (CINGW) |
| Form Type | DEFA14A |
| Filed Date | Aug 23, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, meeting-adjournment, biopharmaceutical
Related Tickers: CING
TL;DR
CING meeting adjourned 8/23. Details TBD.
AI Summary
Cingulate Inc. announced on August 23, 2024, the adjournment of its special meeting. The company, listed on NASDAQ under the ticker CING, is involved in the biopharmaceutical sector. Further details regarding the reason for adjournment or any rescheduled meeting date were not provided in this specific filing.
Why It Matters
The adjournment of a special meeting can indicate ongoing discussions or unresolved issues that may impact shareholder decisions and the company's future strategic direction.
Risk Assessment
Risk Level: medium — Adjournments of shareholder meetings can sometimes signal underlying issues or delays in critical corporate actions.
Key Players & Entities
- Cingulate Inc. (company) — Registrant
- NASDAQ:CING (company) — Stock Ticker
- August 23, 2024 (date) — Date of Press Release and Filing
FAQ
What is the purpose of the special meeting that was adjourned?
The provided filing does not specify the purpose of the special meeting that was adjourned on August 23, 2024.
When will the rescheduled special meeting take place?
The filing announces the adjournment but does not provide a new date or timeline for the rescheduled special meeting.
What is the reason for the adjournment of Cingulate Inc.'s special meeting?
The press release announcing the adjournment does not state the specific reason for the meeting's postponement.
Is this filing a preliminary or definitive proxy statement?
This filing is marked as 'Definitive Additional Materials' and includes a press release dated August 23, 2024, regarding the adjournment of a special meeting.
What is Cingulate Inc.'s primary business?
Cingulate Inc. is identified as a biopharmaceutical company.
Filing Stats: 478 words · 2 min read · ~2 pages · Grade level 12 · Accepted 2024-08-23 16:55:53
Filing Documents
- formdefa14a.htm (DEFA14A) — 20KB
- 0001493152-24-033746.txt ( ) — 21KB
From the Filing
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the SEC Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to 14a-12 CINGULATE INC. (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials. Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. On August 23, 2024, Cingulate Inc. issued the following press release: CINGULATE ANNOUNCES ADJOURNMENT OF SPECIAL MEETING KANSAS a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that it has adjourned its Special Meeting of Stockholders (the “Special Meeting”) in order to provide stockholders additional time within which to vote on all proposals. At this time, there are not present, by remote communication or by proxy, a sufficient number of shares of the Company’s common stock to constitute a quorum. The Company’s Board of Directors continues to believe that that all of the proposals contained in the proxy adjourned the Special Meeting. The adjourned meeting will be held at 11:00 a.m. Central Time on August 28, 2024 at the following url: www.meetnow.global/MCZZ4DG. The record date for the Special Meeting is June 28, 2024. Special Meeting of Stockholders of Cingulate Inc. The adjourned meeting will be held at 11:00 a.m. Central Time on August 28, 2024 at the following url: www.meetnow.global/MCZZ4DG. The Board of Directors unanimously recommends that stockholders vote FOR all proposals on the agenda. Stockholders may cast their vote live by calling toll free at 1-800-652-8683 or online by going to www.envisionreports.com/CING-SP . About Cingulate® Cingulate Inc. (NASDAQ: CING), is a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of attention deficit/hyperactivity disorder (ADHD), Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product candidates, including to treat anxiety disorders. Cingulate is headquartered in Kansas City. Investor Relations Thomas Dalton Vice President, Investor & Public Relations, Cingulate TDalton@cingulate.com 913-942-2301 Matt Kreps Darrow Associates mkreps@darrowir.com 214-597-8200